Recent Advances in Primary and Relapsed Ovarian Cancer — Preclinical and Clinical Research

Dear Colleagues,

Among gynecological cancers, ovarian cancer is the leading cause of death, and it is the fifth most frequent cause of death. Most of the cases are diagnosed in advanced stages leading to a poor prognosis. In primary ovarian cancer, the standard of care is cytoreductive surgery and platinum-based chemotherapy. In recent years, immunotherapy and targeted therapy widened the spectrum of therapeutical options. Despite these therapeutical options, many patients experience a relapse over time. BRCA mutation and HRD testing are included in the current treatment. Many different treatment modalities were added to standard therapy, but a better understanding of genetic and molecular characterization of ovarian cancer and HGSOC is still needed. Furthermore, mechanisms of resistance to therapy, the impact of BRCA1/2 status, and tumor heterogeneity have to be investigated in the future. New treatment options based on a better understanding of the molecular characterization of this cancer and reasons for chemoresistance are needed. This Special Issue will highlight preclinical studies, clinical trials, basic research of genetic testing, tumor cell heterogeneity, the origin of ovarian cancer (Fallopian tube/ovarian tissue), reasons for chemoresistance, and new research ideas in primary and relapsed ovarian cancers.

Dr. Cornelia Bachmann
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.